Navigation Links
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Date:7/8/2008

NEW YORK, July 8 /PRNewswire/ -- Royalty Pharma is pleased to announce that James Reddoch, Ph.D., has joined the company as Executive Vice President, Head of Research. Dr. Reddoch has 17 years of experience in the biotechnology sector. He has spent the last 12 years as an equity analyst, most recently as Managing Director, Biotechnology and Group Head, Healthcare, at FBR Capital Markets. He previously worked at Banc of America Securities, and CIBC World Markets Corp. (now Oppenheimer & Co.). Dr. Reddoch holds a B.A. from Furman University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO )

"The addition of Jim to our management team adds a critical element to our analytical capabilities. He combines a deep scientific knowledge with fundamental research and financial skills," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "As an analyst, Dr. Reddoch has proven to have a unique perspective that has differentiated him from his peers."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with approximately $5 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott's Humira(R), J&J/Centocor's Remicade(R), Pfizer's Lyrica(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

The company has an eleven year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica(R) royalty from Northwestern University, its $650 million purchase of the Remicade(R) royalty from New York University, its $700 million purchase of the Humira(R) royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million.

For more information, go to http://www.royaltypharma.com

Contacts:

Pablo Legorreta, Chief Executive Officer

Alexander B. Kwit, Executive Vice President and General Counsel

Susannah Gray, Executive Vice President and Chief Financial Officer

212-883-0200


'/>"/>
SOURCE Royalty Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech to Establish Separate Operating and Royalty Businesses
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million
4. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
5. Antibody Engineering Company F-Star Buys Back Royalty Obligations
6. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
7. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
8. Drug Royalty Corporation Changes Its Name to DRI Capital
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
11. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent of ... over profits, while only 16 percent believe health insurance ... today. Meanwhile, 36 percent of U.S. adults believe health ... over profits, compared to hospitals (23%). "We ... said Wendy Salomon , vice president of reputation ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... meeting of the North American Spine Society (NASS)1 demonstrate high fusion rates ... of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... One Million ... Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As a ... and their applicability in drug safety assessment, for the industry as a whole. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, a leading ... a collaboration with the Heidelberg University Hospital and the German Cancer Research Center ... the company’s successful launch of its CATS (Capture and Amplification by Tailing ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the ... their offering. The report forecasts the global military biometrics ... The report has been prepared based on an in-depth ... landscape and its growth prospects over the coming years. The report also ...
(Date:12/8/2016)... Dec. 8, 2016 Market Research Future published a half ... global Mobile Biometric Security and Service Market is expected to grow ... Market Highlights: ... , Mobile Biometric Security and ... the increasing need of authentication and security from unwanted cyber threats. ...
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
Breaking Biology News(10 mins):